Cassava Sciences | PTIE - Current Liabilities


Cassava Sciences reported $40.11M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
Amgen USD 24.96B 534M Mar/2026
Biogen USD 3B 350.5M Mar/2026
Cara Therapeutics USD 11.04M 2K Dec/2025
Cassava Sciences USD 40.11M 3.72M Mar/2026
Eisai JPY 340.25B 47.42B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Geron USD 73.57M 40.25M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Novavax USD 342.46M 117.49M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Roche Holding CHF 28B 421M Dec/2025